Literature DB >> 14550694

Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS).

Joachim Schofer1, Michael Schlüter, Anthony H Gershlick, William Wijns, Eulogio Garcia, Erick Schampaert, Günter Breithardt.   

Abstract

BACKGROUND: Sirolimus-eluting stents have been developed to prevent restenosis in the treatment of coronary artery disease. We investigated the risk of restenosis with use of sirolimus-eluting stents compared with bare-metal stents to assess possible differences.
METHODS: We enrolled 352 patients in whom one coronary artery required treatment, with diameter 2.5-3.0 mm and lesion length 15-32 mm. We randomly assigned patients sirolimus-eluting stents (n=175) or bare-metal stents (control, n=177). At 8 months we assessed differences in minimum lumen diameter and binary restenosis within the lesion (restenosis of > or =50% diameter, including 5 mm vessel segments proximal and distal to stented segment). Patients were also followed up for 9 months for major adverse cardiac events. Analysis was by intention to treat.
FINDINGS: Stent implantation was successful in 100% of sirolimus-stent patients and 99.4% of controls. The mean diameter of treated coronary arteries was 2.55 mm (SD 0.37) and mean lesion length was 15.0 mm (6.0). Multiple stents were implanted in 170 (48%) patients. At 8 months, minimum lumen diameter was significantly higher with sirolimus-eluting stents than with control stents (2.22 vs 1.33 mm, p<0.0001). The rate of binary restenosis was significantly reduced with sirolimus-eluting stents compared with control stents (5.9 vs 42.3%, p=0.0001). Significantly fewer patients with sirolimus-eluting stents had major adverse cardiac events at 9 months than did controls (8.0 vs 22.6%, p=0.0002), due mainly to a lower need for target-lesion revascularisations (4.0 vs 20.9%, p<0.0001).
INTERPRETATION: Sirolimus-eluting stents are better than bare-metal stents for treatment of single long atherosclerotic lesions in a coronary vessel smaller than 3 mm in diameter.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14550694     DOI: 10.1016/S0140-6736(03)14462-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  93 in total

1.  Long-term angiographic outcomes of post-sirolimus-eluting stent restenosis in Japanese patients.

Authors:  Nobuyuki Miyai; Noriyuki Kinoshita; Keisuke Oota; Takeshi Yamada; Reo Nakamura; Hidekazu Irie; Tetsuo Hashimoto; Shyunichi Tamaki; Hiroaki Matsubara
Journal:  Heart Vessels       Date:  2010-10-27       Impact factor: 2.037

2.  Matrine inhibits vascular smooth muscle cell proliferation by modulating the expression of cell cycle regulatory genes.

Authors:  Ping Zhu; Ji-mei Chen; Shu-zhen Chen; Cheng Zhang; Shao-yi Zheng; Guang Long; Ji Chen; Zhi-ling Zhou; Rui-xin Fan; Xiao-ping Fan; Yan-fang Chen; Jian Zhuang
Journal:  Acta Pharmacol Sin       Date:  2010-09-13       Impact factor: 6.150

3.  The disutility of restenosis--the impact of repeat percutaneous coronary intervention on quality of life.

Authors:  Marleen M J Ploegmakers; Anneke M Viscaal; Lois Finch; Nancy E Mayo; James M Brophy
Journal:  Can J Cardiol       Date:  2010 Jun-Jul       Impact factor: 5.223

4.  Incidence and predictors of target lesion failure in patients undergoing contemporary DES implantation-Individual patient data pooled analysis from 6 randomized controlled trials.

Authors:  Maayan Konigstein; Mahesh V Madhavan; Ori Ben-Yehuda; Hussein M Rahim; Iva Srdanovic; Fotis Gkargkoulas; Ghazaleh Mehdipoor; Evan Shlofmitz; Akiko Maehara; Björn Redfors; Ankita K Gore; Thomas McAndrew; Gregg W Stone; Ziad A Ali
Journal:  Am Heart J       Date:  2019-04-12       Impact factor: 4.749

Review 5.  Drug eluting stents in 2005.

Authors:  A H Gershlick
Journal:  Heart       Date:  2005-06       Impact factor: 5.994

6.  Contemporary Use of Drug-eluting Stents.

Authors:  William W Chu; Ron Waksman
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-05

7.  Percutaneous coronary intervention: recommendations for good practice and training.

Authors:  K D Dawkins; T Gershlick; M de Belder; A Chauhan; G Venn; P Schofield; D Smith; J Watkins; H H Gray
Journal:  Heart       Date:  2005-12       Impact factor: 5.994

Review 8.  The cost-effectiveness of drug-eluting stents: a systematic review.

Authors:  Suzanne Ligthart; Floortje Vlemmix; Nandini Dendukuri; James M Brophy
Journal:  CMAJ       Date:  2006-12-19       Impact factor: 8.262

9.  Characterizing the spectrum of in-stent restenosis: implications for contemporary treatment.

Authors:  Gordon E Pate; May Lee; Karin Humphries; Eric Cohen; Robert Lowe; Rebecca S Fox; Robert Teskey; Christopher E Buller
Journal:  Can J Cardiol       Date:  2006-12       Impact factor: 5.223

10.  A first-in-man study of sirolimus-eluting, biodegradable polymer coated cobalt chromium stent in real life patients.

Authors:  Ashok Seth; Praveen Chandra; Nagendra S Chouhan; Ashok S Thakkar
Journal:  Indian Heart J       Date:  2012-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.